House bill would have the VA study peptide therapies

H.R. 10212, the PEPTIDES for Veterans Act, was introduced in the U.S. House on September 1, 2026 ^[1]. It was referred to the Subcommittee on Health of the House Committee on Veterans' Affairs on September 8, 2026 ^[1]. That was its latest action as of November 5, 2026 ^[1].

Its stated purpose is to direct the Secretary of Veterans Affairs to study the potential benefits of peptide-based therapies for veterans who receive VA care ^[2]. A bill is a proposal, and this one has not passed the House or the Senate ^[1]. Current status for each peptide is on the Status Tracker ^[1].

More news

• DEA telemedicine flexibilities run through 2026
• FDA advisers review seven peptides for compounding
• FDA letter and a recall target compounded GLP-1 drugs
• FDA proposes keeping GLP-1s off the 503B bulks list
• FDA tells Lilly retatrutide is a drug, not a biologic
• FDA warns 30 telehealth firms over compounded GLP-1 ads
• HHS interim policy covers 6 peptides for compounding
• Most peptides leave FDA's Category 2 list

Status of every peptide

• FDA Peptide Status Tracker

Sources

1. Congress.gov: H.R. 10212, PEPTIDES for Veterans Act
2. Congress.gov: H.R. 10212, bill text

Updated November 5, 2026. Educational information, not medical advice.